You are deep into your due diligence on a fast-growing mid-cap logistics firm. The financials look impeccable: double-digit revenue growth, expanding EBITDA margins, and a healthy debt-to-equity ratio. However, as you...
Imagine you are reviewing a high-performing Indian pharmaceutical firm. Its balance sheet is pristine, and its five-year Return on Equity consistently exceeds 20%. However, if you ignore the broader industry...
You are deep into the annual report of a high-growth mid-cap company. The financial metrics are pristine—margins are expanding, and the balance sheet is lean—yet your intuition nags at you because the promoter's salary...
Imagine you are reviewing the balance sheet of a capital-intensive infrastructure firm listed on the NSE. Your manager asks whether the company's aggressive expansion plans are sustainable, or if the rising leverage...
You are sitting in a conference room in BKC, Mumbai, evaluating a mid-cap pharmaceutical firm that has recently seen its stock price surge following a new drug patent announcement. Your junior analyst presents a...
Imagine you are evaluating a high-growth infrastructure firm in India. The company reports impressive earnings growth for three consecutive quarters, and the management is aggressively expanding its manufacturing...